A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers.

Inclusion criteria

• A body mass index (BMI) between 18.0 and 32.0 kilogram per square meter (kg/m2), inclusive, and weighing >/=50 kg.
• Agreement to comply with measures to prevent pregnancy and restrictions on egg and sperm donation

Exclusion criteria

• Women of childbearing potential, women who are pregnant or breastfeeding, or intending to become pregnant during the study or within 14 days after the final dose of entrectinib or have a pregnant partner
• A clinical significant medical history of gastrointestinal surgery (e.g., gastric bypass) or other gastrointestinal disorder (e.g., malabsorption syndrome) that might affect absorption of medicines from the gastrointestinal tract
• Presence of a clinically significant disease, illness, medical condition or disorder, or any other medical history determined by the investigator to be clinically significant and relevant
• Clinically significant change in health status, or any major illness, or clinically significant acute infection or febrile illness
• Use of moderate or potent inhibitors or inducers of CYP P450 3A4 enzyme or P-gp transporter, or use of other prohibited medications
• Participation in any other clinical study involving an investigational medicinal product (IMP) or device
• A positive test result for hepatitis B, hepatitis C (HCV), or human immunodeficiency virus (HIV)
• Current smokers and those who have smoked, or users of e-cigarettes and nicotine replacement products within the last 12 months
• Known history of clinically significant hypersensitivity, or severe allergic reaction, to entrectinib or related compounds